

DATE: September 12th, 2016

TO: All VFC Providers

FROM: NDHHS Immunization Program

RE: HIBERIX brand available 2016-9-b

Clinics are offered another brand choice for Hib vaccine. If a clinic wants to use Hiberix it is available to order in NESIIS.

Hiberix previously was only indicated for the booster dose in the series but indications have changed:

- Hiberix is a vaccine indicated for active immunization for the prevention of invasive disease caused by *Haemophilus influenzae* type b.
- Hiberix is manufactured by GlaxoSmithKline.
- Hiberix is FDA approved for use in children 6 weeks through 4 years of age (prior to fifth birthday)
- Dosage & Administration: A 4-dose series (0.5 mL each) given by intramuscular injection. Refer to the package insert for full details.
 - Primary series: One dose each at 2, 4, and 6 months of age. The first dose may be given as early as 6 weeks of age.
 - Booster: One dose at the recommended age of 15 through 18 months of age; however, CDC and ACIP state the booster dose may be given as early at 12-15 months.
- A MMWR on Hiberix titled -The Food and Drug Administration Approval for Use of Hiberix as a 3-Dose Primary Haemophilus influenzae Type b (Hib) Vaccination Series was published on April 29, 2016. It can be found at <http://www.cdc.gov/mmwr/volumes/65/wr/mm6516a3.htm>

Refer to the updated Advisory Committee on Immunization Practices - Vaccines for Children Resolution for updates on the use of Hib vaccine in certain populations

<http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/02-13-2-hib.pdf>

We greatly value a successful collaboration between your clinic and our program. Should you have any questions please contact your clinic's assigned Community Health Nurse or call the NDHHS Immunization Program at (402) 471-6423 or (800) 798-1696.

Thank you.

The NDHHS Immunization Program